Zhitong Financial App News, China Biopharmaceutical (01177) announced that the national Class 1 innovative drug TQ-A3334 “TLR7 agonist” independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), a subsidiary of the Group, has announced the latest breakthrough summary parallel session (Late-Breaking Abstract Parallel Session) at the 2026 American Society for Liver Disease Research (AASLD) annual meeting (Late-Breaking Abstract Parallel Session) to announce the results of the Phase II clinical study in the form of an oral report.

TQ-A3334 is a novel, highly selective oral Toll-like receptor 7 (TLR7) agonist. TLR agonists restore depleted innate and adaptive immunity and enhance antiviral defenses. TQ-A3334 has shown good safety and initial anti-hepatitis B virus (HBV) activity in previous clinical studies. The purpose of this phase II study was to evaluate the efficacy and safety of TQ-A3334 combined with riboglycine (acid) analogs (NAs) in the treatment of patients with chronic HBV infection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.